CD274 and neoplasm: Furthermore, the combination of FDA-approved PARP inhibitors with immunotherapies such as anti- PD-1/PD-L1 is based on the hypothesis that PARP inhibitors can restore anti-tumor immune response, particularly in HR deficiency cells, thereby synergizing with ICI to enhance the anti-tumor effect [54].